Mirrx Therapeutics, a Lyngby, Denmark-based developer of a technology aimed at reducing unintended effects on gene activity, has completed an undisclosed seed financing round.
SEED Capital, Inventure Capital and Vecata Invest participated in the funding.
The capital infusion will enable the company to achieve in vivo proof of concept for its microRNA-blocking (called “Blockmir”) technology, as well as to strengthen its intellectual property portfolio.
The blockmir compounds being developed by Mirrx have relevance for all major disease areas and reduce risks of unwanted side-effects dramatically, as compared to other compounds interfering with microRNA pathways.
Mirrx Therapeutics acquired its Blockmir technology from Stealth Biotech Aps.